货号:A2305170 同义名: Menin-MLL inhibitor 24 oxalate
Bleximenib (Menin-MLL inhibitor 24) oxalate 是一种 Menin-mixed-lineage leukemia 1 (menin-MLL) 抑制剂,可用于癌症研究。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | BET ↓ ↑ | bromodomain ↓ ↑ | BRPF ↓ ↑ | CBP/beta-catenin ↓ ↑ | p300/CBP ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MS436 |
++
BRD4 (2), Ki: 0.34 μM BRD4 (1), Ki: <0.085 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
CPI-203 |
+++
BRD4, IC50: 37 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
GSK1324726A |
+++
BRD2, IC50: 31 nM BRD4, IC50: 22 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
PFI-1 |
++
BRD2, IC50: 98 nM BRD4, IC50: 0.22 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Apabetalone |
+
BD2, IC50: 0.51 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
(+)-JQ1 |
+++
BRD4 (1), IC50: 77 nM BRD4 (2), IC50: 33 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
I-BET151 |
+
BRD3, IC50: 0.25 μM BRD4, IC50: 0.5 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Molibresib |
+++
BET proteins, IC50: 35 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
I-BRD9 |
+++
BRD9, pIC50: 7.3 BRD4, pIC50: 5.3 |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
BI-7273 |
++++
BRD7, IC50: 117 nM BRD9, IC50: 19 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Pelabresib |
+++
BRD4-BD1, IC50: 39 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
ARV-825 |
+++
BRD4 BD2, Kd: 28 nM BRD4 BD1, Kd: 90 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Birabresib | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||||
BI 2536 |
+++
BRD4, Kd: 37 nM |
c-Myc | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Bromosporine |
++
BRD2, IC50: 0.29 μM BRD9, IC50: 0.122 μM |
++++
CECR2, IC50: 17 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
XMD8-92 |
++
BRD4 (1), Kd: 170 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Mivebresib | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
BI-9564 |
++++
BRD9, Kd: 5.9 nM BRD7, Kd: 73 nM |
++
CECR2, Kd: 77 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
AZD5153 6-Hydroxy-2-naphthoic acid |
++++
FL-BRD4, IC50: 5 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
PLX51107 |
++++
BRD4 BD2, Kd: 1.7 nM BRD3 BD1, Kd: 2.1 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
FL-411 |
+
BRD4(1), IC50: 0.43 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
ABBV-744 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
dBET6 |
++++
BRD4, IC50: 14 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
dBET1 |
++++
BRD4, IC50: 20 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
MZ1 |
++++
Brd3(BD2), Kd: 13 nM Brd2(BD2), Kd: 62 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
dBET57 |
+
BRD4BD1, DC50: 500 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
SF2523 |
+
BRD4, IC50: 241 nM |
DNA-PK | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
INCB054329 |
++++
BRD3-BD1, IC50: 9 nM BRD4-BD1, IC50: 119 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
INCB-057643 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
(E/Z)-ZL0420 |
+++
BRD4 BD1, IC50: 27 nM BRD4 BD2, IC50: 32 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
BMS-986158 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
BRD4 Inhibitor-10 |
++++
BRD4-BD2, IC50: 41 nM BRD4-BD1, IC50: 5 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
A1874 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Y06036 |
++
BRD4 (1), Kd: 82 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Alobresib | ✔ | NF-κB | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
ODM-207 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
GSK778 |
+++
BRD2-BD1, IC50: 75nM BRD4-BD1, IC50: 143 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
SRX3207 |
+
BRD41, IC50: 3070 nM BRD42, IC50: 3070 nM |
Syk | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
GSK046 |
+++
BRD4BD2, IC50: 214 nM BRD3BD2, IC50: 98 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
GSK620 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Thalidomide-NH-C4-NH-Boc | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Trotabresib | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
NHWD-870 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
CFT8634 |
++++
BRD9, DC50: 3 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
GSK2801 |
++
BAZ2B, Kd: 136 nM BAZ2A, Kd: 257 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
KG-501 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
UNC 669 |
+
L3MBTL3, IC50: 35 μM L3MBTL4, IC50: 6 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
PFI-3 |
+++
SMARCA2A, Kd: 72 nM SMARCA4, Kd: 55 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
UNC1215 |
+++
L3MBTL3- D274A, IC50: 3.5 μM L3MBTL3, IC50: 120 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
EED226 |
++
PRC2, Kd: 114 nM EED, Kd: 82 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
BRD9539 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
UNC926 |
+
L3MBTL1, Kd: 3.9 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
666-15 |
++
CREB, IC50: 81 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
UNC6852 |
+
EED, IC50: 247 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
BAZ1A-IN-1 |
+
BAZ1A, Kd: 0.52 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
PFI-4 |
++
BRPF2, IC50: 7.9 μM BRPF1, IC50: 80 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
OF-1 |
++
BRPF2, Kd: 500 nM BRPF1B, Kd: 100 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
GSK-5959 |
++
BRPF3, pIC50: 7.1 BRPF2, pIC50: 5.2 |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
GSK6853 |
++++
BRPF1, pIC50: 8.1 |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
NI-42 |
++++
BRPF1, IC50: 48 nM BRPF3, IC50: 260 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
E-7386 |
+++
CBP/beta-catenin, IC50: 0.0484 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
I-CBP112 |
++
p300, Kd: 167 nM CBP, Kd: 151 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Histone Acetyltransferase Inhibitor II |
+
p300, IC50: 5 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
C646 |
+
p300/CBP, Ki: 400 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Anacardic Acid |
+
p300/CBP, IC50: 8.5 μM PCAF, IC50: 5 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
SGC-CBP30 |
++++
EP300, IC50: 38 nM CREBBP, IC50: 21 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Nordihydroguaiaretic acid | ✔ | HER2,IGF-1R | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Curcumin |
+
p300, IC50: ~25 μM |
Nrf2,Ferroptosis,NF-κB | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
PF-CBP1 HCl |
++
p300/CBP, IC50: 363nM CREBBP, IC50: 125nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
CPI-637 |
+++
EP300, IC50: 0.051 μM CBP, IC50: 0.03 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Foscenvivint | ✔ | β-catenin | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
A-485 |
++
p300 HAT, IC50: 0.06 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
GNE-781 |
+
BRD4(1), IC50: 5100 nM |
++++
CBP, IC50: 0.94 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
NEO2734 |
+++
BET, IC50: <30 nM |
+++
p300/CBP, IC50: <30 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.45mL 0.29mL 0.14mL |
7.25mL 1.45mL 0.72mL |
14.50mL 2.90mL 1.45mL |
CAS号 | 2866179-95-3 |
分子式 | C34H52FN7O7 |
分子量 | 689.818 |
别名 | Menin-MLL inhibitor 24 oxalate |
运输 | 蓝冰 |
存储条件 |
粉末 Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
溶解度 | |
动物实验配方 |